详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

HBV precore G1896A mutation promotes growth of hepatocellular carcinoma cells by activating ERK/MAPK pathway

16| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C

作者：

机构： [1]Institute of Medical and Health Science, Hebei Medical University, Shijiazhuang, 050017, China [2]Department of Pathogen Biology, Hebei Medical University, Shijiazhuang, 050017, China. [3]Department of Gastroenterology and Hepatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China. [4]State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega Science, Chinese Academy of Sciences, Wuhan, 430207, China. [5]Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.

出处：

DOI：

ISSN：

关键词： HBV G1896A mutation hepatocellular carcinoma (HCC) proliferation apoptosis ERK/MAPK

摘要：

Chronic hepatitis B virus (HBV) infection is one of the leading causes of hepatocellular carcinoma (HCC). The HBV genome is prone to mutate and several variants are closely related to the malignant transformation of liver disease. G1896A mutation (G to A mutation at nucleotide 1896) is one of the most frequently observed mutations in the precore region of HBV, which prevents HBeAg expression and is strongly associated with HCC. However, the mechanisms by which this mutation causes HCC are unclear. Here, we explored the function and molecular mechanisms of the G1896A mutation during HBV-associated HCC. G1896A mutation remarkably enhanced the HBV replication in vitro. Moreover, it increased tumor formation and inhibited apoptosis of hepatoma cells, and decreased the sensitivity of HCC to sorafenib. Mechanistically, the G1896A mutation could activate ERK/MAPK pathway to enhanced sorafenib resistance in HCC cells and augmented cell survival and growth. Collectively, our study demonstrates for the first time that the G1896A mutation has a dual regulatory role in exacerbating HCC severity and sheds some light on the treatment of G1896A mutation-associated HCC patients.Copyright © 2023 The Authors. Publishing services by Elsevier B.V. All rights reserved.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院分区：

出版当年[2023]版：

大类 | 3 区医学

小类 | 3 区病毒学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区病毒学

JCR分区：

出版当年[2023]版：

Q2 VIROLOGY

最新[2023]版：

Q2 VIROLOGY

影响因子： 4.3 最新[2023版] 4.3 最新五年平均 4.3 出版当年[2023版] 4.3 出版当年五年平均 5.5 出版前一年[2022版]

第一作者：

第一作者机构： [1]Institute of Medical and Health Science, Hebei Medical University, Shijiazhuang, 050017, China [2]Department of Pathogen Biology, Hebei Medical University, Shijiazhuang, 050017, China.

共同第一作者：

通讯作者：

通讯机构： [1]Institute of Medical and Health Science, Hebei Medical University, Shijiazhuang, 050017, China [2]Department of Pathogen Biology, Hebei Medical University, Shijiazhuang, 050017, China. [3]Department of Gastroenterology and Hepatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China. [4]State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega Science, Chinese Academy of Sciences, Wuhan, 430207, China. [5]Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]C/EBP alpha Regulates FOXC1 to Modulate Tumor Growth by Interacting with PPAR gamma in Hepatocellular Carcinoma [2]Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial [3]ERK-1与Cyclin D1在肝细胞肝癌组织中的表达 [4]miR-4306通过MAPK/ERK信号通路抑制血管紧张素Ⅱ诱导的主动脉夹层的形成 [5]PD-1/PD-L1 Interaction Upregulates YAP1 Expression in HepG2 Cells Through MAPK/ERK Pathway [6]阿帕替尼一线治疗晚期肝细胞癌的前瞻性、随机、开放、全国多中心Ⅱ期临床试验 [7]miR-4306通过MAPK/ERK信号通路抑制血管紧张素Ⅱ诱导的主动脉夹层的形成 [8]肝癥口服液对二乙基亚硝胺诱发大鼠肝癌的阻断作用 [9]4-羟雌二醇与肿瘤关系的研究进展 [10]MicroRNA-27a promotes tumorigenesis in tongue squamous cell carcinoma by enhancing proliferation, migration and suppressing apoptosis.